At a glance
Stallergenes Greer is a fully integrated global biopharmaceutical company specialising in the research, diagnosis and treatment of respiratory, food, and venom allergies through the development and commercialisation of allergen immunotherapy (AIT) products and services. AIT is an allergy treatment designed to treat the underlying cause of the disease by rebalancing the immune system. Ait can alter the natural course of allergies and is a therapeutic class capable of modifying disease progression.
Stallergenes Greer boasts a broad global footprint and extensive allergen and
finished AIT product manufacturing capabilities.
production of sublingual (solutions and tablets), and subcutaneous AIT products
source materials (pollen) and securing of house dust mite strains
subcutaneous named patient products
source materials, bulk allergens and supplies for human and veterinary use
source materials (pollen)
bulk allergens and custom-order products
![](/sites/default/files/annual-reports/2023/numbers_0.png)
![](/sites/default/files/annual-reports/2023/titre1.png)
![](/sites/default/files/annual-reports/2023/titre2.png)
![](/sites/default/files/annual-reports/2023/sg-2023-annreport-uk-final-print2-copie-11.png)
Four pillars form the framework of our corporate responsibility programme, Care Beyond Allergy. They emphasise our responsibility both as a company and as an employer and focus on areas in which we can make a difference: society, environment, social and governance.
![](/sites/default/files/annual-reports/2023/sg-2023-annreport-uk-final-print2-11-2.png)
![](/sites/default/files/annual-reports/2023/titre3.png)
The foundation’s mission is “to create healthier futures for all” by: focusing on scientific research to bolster innovation and precision medicine; supporting academic initiatives to develop future generations of allergy healthcare professionals; and engaging in climate action and environmental protection to progress the prevention and treatment of allergies.
What’s new
ADDED TO PORTFOLIO
AND UK SUBSIDIARIES
LAUNCH IN FRANCE
END OF RECRUITMENT / LAUNCH IN 2024
REGISTRATION IN FRANCE
DRUG DOSSIER SUBMISSION